Science and Technology
December 3, 2014

Executive Management

 

arrow

Executive Management

Richard Wagner, Ph.D – President and CEO
dotted-line
Christelle Huguet, Ph.D – CSO
dotted-line
Matthew A. Clark, Ph.D – S.V.P., Chemistry
dotted-line
Steffen Helmling, Ph.D – V.P., Business Development
dotted-line
Harvey Kaufman – S.V.P., Organizational Development
dotted-line
Ed Koval, M.B.A. – S.V.P., Corporate Development
dotted-line
Terry Loding, MBA V.P., Corporate Strategy and Alliances
dotted-line
Jeffrey Troderman, C.P.A., M.B.A. – CFO
dotted-line

Richard Wagner, Ph.D – President and CEO

xchem

Dr. Wagner co-founded X-Chem in 2009, and is the President, CEO, and member of the Board of Directors. He is member of the Board of Directors of Xios, Inc. and Founder and member of the Board of Directors of  X-Rx, Inc., spin-out companies of X-Chem focused on oncology and inflammatory disease. In addition, he founded X-BODY, sold to Juno Therapeutics in 2015. Dr. Wagner was President and CEO of SRU Biosystems, Inc. from 2007 to 2012. Prior to joining SRU, he was Executive Vice President of Research at Praecis Pharmaceuticals, Inc., where he was an inventor of the DirectSelect small molecule screening technology that led to the creation of a ten billion compound screening library. Praecis was acquired by GlaxoSmithKline in 2007. Prior to joining Praecis, Dr. Wagner started operations at Phylos, Inc. in July 1997 as Senior Vice President of Research. At Phylos he was an inventor on several technologies, including a class of antibody mimetics being developed by Bristol Myers Squibb, now called Adnectins™. Earlier, Dr. Wagner had been Director of Cell Biology and a member of management team at Gilead Sciences, Inc. Dr. Wagner received his B.S. in Biochemistry from Trinity College and his Ph.D. in Chemistry from Brown University.

Christelle Huguet, Ph.D – E.V.P. and Chief Science Officer

xchem

Dr. Huguet brings 20 years of Drug discovery and development experience, most recently Head of Internal Research at Alexion focusing on rare and devastating diseases. Dr Huguet previously held a number of leadership positions at Pfizer, including Chief Scientific Officer of the Inflammation & Remodeling Research Unit, Chief Scientific Officer of Worldwide Pharmacokinetics Dynamics & Metabolism, Head of the Genito-Urinary Therapeutic Area, Head of Allergy & Respiratory Research. Dr Huguet directed strategy and research in rare diseases, sexual health, endometriosis, overactive bladder, incontinence, interstitial cystitis, chronic pulmonary diseases and chronic kidney diseases. Dr Huguet has delivered more than 10 NMEs spanning small molecules, RNAs, biologics, oral, inhaled and/or injectables, and led several programs into PhI and Phase IIa/b clinical trials.

Dr. Huguet studied in France, Germany and Switzerland, receiving a French University Diplomas in Technology (DUT) in applied biology and biochemistry, and a European Engineering degree in biotechnology sciences. She received a Ph.D. in molecular and cellular biology from the Institute Pasteur in France.

Matthew A. Clark, Ph.D – S.V.P., Chemistry

xchem

Dr. Clark joined X-Chem in 2010 as VP of Chemistry, and now serves as SVP for Research. Before coming to X-Chem, Dr. Clark was Director of Chemistry at Praecis Pharmaceuticals, later acquired by GlaxoSmithKline in 2007, where he led a group responsible for design and synthesis of DNA-encoded chemical libraries. At Praecis, Dr. Clark played a key role in the early development and implementation of the DNA-encoded library platform. Dr. Clark received his B.S. in Biochemistry from the University of California, San Diego, and his Ph.D. in Chemistry from Cornell University. He conducted post-doctoral studies at the Massachusetts Institute of Technology.

Steffen Helmling, Ph.D – V.P., Business Development

xchem

Dr. Helmling joined X-Chem as Vice President of Business Development in May 2013, following his tenure at PolyMedix Inc., a clinical-stage company developing novel antibiotics, where he was Vice President of Business Development responsible for out-licensing the company’s key assets. A biochemist by training, he has significant experience in biomedical R&D in both academic and corporate settings. His background includes positions in drug discovery research, project and alliance management, and business development. Prior to PolyMedix, Dr. Helmling held various positions at NOXXON Pharma, a company developing nucleic acid-based drugs, most recently serving as Executive Vice President, Business Development. He has negotiated, executed and managed drug discovery partnerships with various pharmaceutical companies, including Pfizer, Roche, and Eli Lilly. He holds a Ph.D. in Biochemistry from the Sackler School of Biomedical Sciences at Tufts University.

Harvey Kaufman – S.V.P., Organizational Development

xchem

Harvey Kaufman is an Organization Development professional helping leaders and leadership teams, in the US and abroad, design effective strategies and creative, enduring solutions to overcome their most intractable problems. He has studied and written about the role of values in organizations and speaks at conferences and universities on topics related to OD, coaching and leadership. Harvey has managed the design and delivery of $1M+ client engagements, planned and facilitated senior leadership team off-sites and managed the development of training and consulting practices. With over ten years of management and executive leadership experience, Harvey has firsthand knowledge of the challenges of leadership and the difference leaders can make in an organization’s performance. His deep knowledge of the tools and processes for effective leadership yields not only greater degrees of collaboration, but also teams that are better equipped to deal with the challenges they face on their own. His innovative problem solving and consulting and facilitation skills allow clients to access untapped resources within their organization resulting in greater participation, productivity and commitment. Harvey received a BA in American Literature from the University at Albany (NY) and a Master’s Degree in Social Work from New York University. He has served in executive leadership roles in health care organizations and has in-depth knowledge of group dynamics and how they play out in work settings.

Ed Koval, M.B.A. – S.V.P., Corporate and Business Development

xchem

Ed Koval joined X-Chem in June 2013 as a strategic consultant and more recently as senior vice president of corporate development.   Mr. Koval bring more than 20 years of strategy, business / corporate development and finance experience to the company.   Drawing on in-house and consulting insights acquired during several stints in large pharma and emerging biotechs, Ed’s experience cuts across the entire R&D and commercialization value chain as well as multiple therapeutic areas and discovery platforms.  His transactions, both from the buy and sell sides, include the entire range of corporate agreements, from licenses and collaborations to Joint Ventures, financings and M&A.  Mr. Koval started his career at Merck as a financial analysis and licensing transaction manager.  He later joined Chiron as a corporate development director and Novartis as a VP of business development and alliance management for the cardiovascular-metabolic, neuroscience and vaccine businesses.   More recently Ed was head of corporate development at Veloxis, a specialty pharmaceuticals company.  Mr. Koval holds B.S. and M.S. degrees in engineering from NYU and RPI as well as an M.B.A from the MIT Sloan School of Management.

Terry Loding, MBA – V. P., Corporate Strategy and Alliances

xchem

Mr. Loding joined X-Chem in 2016 and is currently serving as the Vice President of Corporate Strategy and Alliances. Prior to joining X-Chem, Mr. Loding has held positions of increasing responsibility in clinical development services, business development and corporate strategy in both global pharmaceutical (Pharmacia) and contract research organizations (Scirex, Kendle, Cmed and PPD). From 1998 – 2010, Mr. Loding worked as data management professional serving initially as functional leader for individual clinical trials and subsequently promoted to positions of line, site and regional management ultimately leading teams of more than 350 people. In the last five years prior to joining X-Chem, Mr. Loding was at PPD where he led multiple, high value strategic partnerships as Senior Director, Alliance Management and most recently served as Executive Director, Strategic Client Solutions focusing on the delivery of a portfolio of corporate strategic projects aimed at sustaining and improving PPD’s competitiveness in the market place. Mr. Loding received his B.S. in Psychology from Loyola University Chicago and an MBA from Elon University, Love School of Business.

Jeffrey Troderman, CPA, MBA – Chief Financial Officer

xchem

Mr. Troderman has over 25 years of financial management and consulting experience culminating in his current position as CFO of X-Chem, Inc. Prior to joining X-Chem, he spent nearly 15 years as a Principal at two regional consulting firms where he served as Interim CFO for a broad client base, including many Life Science Companies. Mr. Troderman began his career and became a Certified Public Accountant after gaining valuable experience at both BDO and KPMG. He holds an M.B.A. from Babson College, a B.B.A. in Accounting from the University of Massachusetts at Amherst and is also a candidate for a J.D./L.L.M. in Tax Law at Suffolk University. Mr. Troderman also serves as a Neutral Arbitrator for FINRA .